Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome

Abstract

Objective: Possibly due to a deficiency of insulin mediators, polycystic ovary syndrome (PCOS) is often associated with insulin resistance (IR) and hyperinsulinemia, likely responsible for an elevated production of reactive oxygen species. We investigated oxidative-related alterations in erythrocytes and anti-inflammatory effects of inositol in women with PCOS before and after treatment with myo-inositol (MYO). Methods: Twenty-six normal-weight PCOS patients were investigated before and after MYO administration (1200 mg/day for 12 weeks; nZ18) or placebo (nZ8) by evaluating serum testosterone, serum androstenedione, fasting serum insulin, fasting serum glucose, insulin area under the curve (AUC), and glucose AUC after oral glucose tolerance test and homeostasis model of assessment-IR. In erythrocytes, band 3 tyrosine phosphorylation (Tyr-P) level, glutathione (GSH) content, and glutathionylated proteins (GSSP) were also assessed. Results: Data show that PCOS patients' erythrocytes underwent oxidative stress as indicated by band 3 Tyr-P values, reduced cytosolic GSH content, and increased membrane protein glutathionylation. MYO treatment significantly improved metabolic and biochemical parameters. Significant reductions were found in IR and serum values of androstenedione and testosterone. A significant association between band 3 Tyr-P levels and insulin AUC was found at baseline but disappeared after MYO treatment, while a correlation between band 3 Tyr-P and testosterone levels was detected both before and after MYO treatment. Conclusions: PCOS patients suffer from a systemic inflammatory status that induces erythrocyte membrane alterations. Treatment with MYO is effective in reducing hormonal, metabolic, and oxidative abnormalities in PCOS patients by improving IR.

Sodium intake, sodium excretion, and cardiovascular risk: involvement of genetic, hormonal, and epigenetic factors

“…In the majority of cases, PCOS is a genetic disease related to insulin resistance, which predisposes to obesity, hypertension, preeclampsia, and metabolic syndrome. Insulin resistance is a characteristic of both obese and lean patients with PCOS . Treatment with healthy lifestyle, metformin, or inositol could prevent the progression to diabetes mellitus and metabolic and cardiovascular risk later in life.…”

“…Insulin resistance is a characteristic of both obese and lean patients with PCOS. 10 Treatment with healthy lifestyle, metformin, or inositol could prevent the progression to diabetes mellitus and metabolic and cardiovascular risk later in life. It is well known that these patients are predisposed to hypertension and preeclampsia, and, therefore, regulated salt intake is also important to reduce the risk associated with genetic predisposition.…”

Nutrients as novel therapeutic approaches for metabolic disturbances in polycystic ovary syndrome

“…whole grains, seeds, and fruits) and also can be produced from glucose in the human body (Carlomagno and Unfer, 2011[10]). Evidence have shown that this nutrient could have a helpful role in decreasing the hormonal profile, oxidative abnormalities, and as well as the metabolic factors in patients with PCOS, probably due to the amelioration of insulin resistance in these patients (Costantino et al, 2009[13]; Donà et al, 2012[16]). In a placebo-controlled trial, women with PCOS were randomized to receive either oral myo-inositol (4 g/d) plus folic acid (400 mcg/d) or folic acid alone for 12-16 weeks (Costantino et al, 2009[13]).…”

“…Several studies have reported to date the positive effects of myo-inositol and D-chiro-inositol on clinical, metabolic, endocrine, hormonal, and oxidative abnormalities in women with PCOS. Based on these observations, this naturally occurring compound may represent an alternative or complementary care to metformin treatment in PCOS patients (Donà et al, 2012[16]).…”

Maternal and Fetal Outcomes in Preeclampsia: Interrelations Between Insulin Resistance, Aldosterone, Metabolic Syndrome, and Polycystic Ovary Syndrome

“…PE is also characterized by increased inflammatory status, which may be promoted by the altered placental perfusion leading to the release of cytotoxic factors into the circulation, increased vascular tone, and endothelial dysfunction . The pro‐oxidative status is also present in PCOS and is involved in the increased metabolic, cardiovascular, and obstetric complications seen in the disease …”